Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: [[ticker:RARE]]) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an advisor through the end of the year. Aimmune is preparing to file for FDA approval of AR101, the company’s experimental immunotherapy for peanut allergy.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.